Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab. Report of one case;Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab. Reporte de un caso

Revista Medica de Chile

Volumn 137, Issue 1, 2009, Pages 88-93

  Yáñez, Jorge V ^a   Cisternas, Marcela M ^a   Saldías, Velia H ^b   Saldías, Fernando S ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

Dermatomyositis; Pneumonia; Rituximab

Indexed keywords

ANTIRHEUMATIC AGENT; CREATINE KINASE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; CASE REPORT; DERMATOMYOSITIS; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MUSCLE WEAKNESS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CREATINE KINASE; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MUSCLE WEAKNESS;

EID: 65549137205     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. MARIE I, HACHULLA E, HATRON PY, HELLOT MF, LEVESQUE H, DEVULDER B ET AL. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230-7.
2. DICKEY BF, MYERS AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984; 14: 60-76.
3. TAZELAAR HD, VIGGIANO RW, PICKERSGILL J, COLBY TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141: 727-33.
4. MARIE I, HATRON PY, HACHULLA E, WALLAERT B, MICHON-PASTUREL U, DEVULDER B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998; 25: 1336-43.
5. AIRIO A, KAUTIAINEN H, HAKALA M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25: 234-9.
6. EPLER GR, COLBY TV, MCLOUD TC, CARRINGTON CB, GAENSLER EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312: 152-8.
7. IMASAKI T, YOSHII A, TANAKA S, OGURA T, ISHIKAWA A, TAKAHASHI T. Polymyositis and Sjögren's Syndrome associated with bronchiolitis obliterans organizing pneumonia. Intern Med 1996; 35: 231-5.
8. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
9. KING TE JR. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005; 172: 268-79.
10. CORDIER JF. Cryptogenic organising pneumonia. Eur Respir J 2006; 28: 422-46.
11. DOUGLAS WW, TAZELAAR HD, HARTMAN TE, HARTMAN RP, DECKER PA, SCHROEDER DR ET AL. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182-5.
12. COTTIN V, THIVOLET-BÉJUI F, REYNAUD-GAUBERT M, CADRANEL J, DELAVAL P, TERNAMIAN PJ ET AL. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245- 50.
13. KANG EH, LEE EB, SHIN KC, IM CH, CHUNG DH, HAN SK, SONG YW. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology 2005; 44: 1282-6.
14. MARIE I, HACHULLA E, CHÉRIN P, DOMINIQUE S, HATRON PY, HELLOT MF ET AL. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614-22.
15. YTTERBERG SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep 2006; 8: 167-73.
16. GOTTENBERG J, GUILLEVIN L, LAMBOTTE O, COMBE B, ALLANORE Y, CANTAGREL A ET AL. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
17. MOK CC, HO LY, TO CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007; 34: 1864-8.
18. BRULHART L, WALDBURGER JM, GABAY C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65: 974-5.
19. LEVINE TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
20. CRAGG MS, WALSHE CA, IVANOV AO, GLENNIE MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-74.